Addex Therapeutics

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Addex to Receive CHF850,000 ($900,000) of Additional Funding ; Addex 's Reserved Indications Expanded to include Chronic Cough

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Geneva, Switzerland, August 12 , 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

Ad Hoc Announcement Pursuant to Art. 53 LR

Addex Completes $4.2 Million Equity Financing

Addex Raises $4.2 million in Equity Financing

Addex Therapeutics is usually under the radar on Wall Street, but today ADXN stock is moving fast on the heels of a critical company update. The post Why Is Addex Therapeutics (ADXN) Stock Up 100% Today?

Why Is Addex Therapeutics (ADXN) Stock Up 100% Today?

Addex Therapeutics Ltd (NASDAQ: ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share capital from CHF 1.00 to CHF 0.01 following the expiration of a period of two months after the third creditor call in The Swiss Gazette of.

What's Happening With Addex Therapeutics Shares Today

Addex Completes Reduction in Nominal Value of Shares

Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.

Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study

Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ: ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment.

Why Shares Of Addex Therapeutics Are Falling Today

Addex Therapeutics Ltd (NASDAQ: ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients.  Data readout from the trial was expected in 1H of 2023.

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

COVID-19 related challenges negatively impacted patient recruitment

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Geneva, Switzerland , May 1 9 , 202 2   - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Geneva, Switzerland , May 1 3 , 202 2   - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy.

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates

Addex Reports Q1 2022 Financial Results

Top-line Data Schedule d to Report in Q2 2022

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?

Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call Transcript

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates

Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

Geneva, Switzerland, March 7 , 20 2 2 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results on Thursday, March 10, 2022. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.

Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022

Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade

Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ: ADXN) have collaborated to investigate a potential therapy for CMT type 1A (CMT1A). Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited neurological disorder that affects the peripheral nerves.

Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder

News for Addex Therapeutics Stock (ADXN)